Limits...
Should Cell Culture Platforms Move towards EV Therapy Requirements?

Aiastui A - Front Immunol (2015)

View Article: PubMed Central - PubMed

Affiliation: Biodonostia Health Research Institute, Cell Culture Platform , Donostia-San Sebastián , Spain.

AUTOMATICALLY GENERATED EXCERPT
Please rate it.

Progress in translational medicine crucially depends on close collaborations between three areas: technology development, research, and hospitals... This combination allows a research idea (or hypothesis) to be developed into a real concept (or product), thus producing substantial benefits to citizens... Such synergy between these areas is beginning to be found in health research institutes located in close vicinity to hospitals... Additionally, increasing developments on cell transplantation-based therapies in hospitals is leading to hand-in-hand co-working between clinicians and scientists through cell culture platforms and is evoking an internal transformation... This quality control should include at least a flow cytometry-based characterization, an ELISA-based quantification, and a nanoparticle tracking, besides purity assessment and exhaustive analysis to ensure the absence of mycoplasma, adventitious agents, and endotoxins... The establishment of EV-based therapies will lead to standardized production and manipulation protocols following good manufacturing practices (GMPs), as well as quality controls to ensure the safety and efficacy of the treatments... Hence, how will these therapies impact cell culture platforms? In addition, even if the EVs production and packing is performed in an external CDMO, resuspension of the cryopreserved EVs can be performed in the platform in our biosecurity flow hoods... This way, the EVs delivery to the hospital, ready to inject, will be achieved a minimum time, as we are already operating with other cell therapies... Bearing all this in mind if the cell culture platform would have to go toward EVs therapy, I would transform part of the platform in a “EVs sample quality service” (Figure 1)... Otherwise, a big construction work with its high costs and complications would be difficult to face... In conclusion, EVs therapies may have a great impact in the close future as new cell-based therapeutic approach; therefore, I will keep a sharp eye on EVs therapies future publications to envision the transformation of our cell culture platform toward a “EVs quality service. ” The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

No MeSH data available.


Cell culture platform is placed in between research, hospital, and technological areas. EVs therapies derived from hospitals could transform part of the cell culture platform in a EVs sample quality service and simultaneously EV resuspension point prior to human injection.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4309209&req=5

Figure 1: Cell culture platform is placed in between research, hospital, and technological areas. EVs therapies derived from hospitals could transform part of the cell culture platform in a EVs sample quality service and simultaneously EV resuspension point prior to human injection.

Mentions: Bearing all this in mind if the cell culture platform would have to go toward EVs therapy, I would transform part of the platform in a “EVs sample quality service” (Figure 1). Otherwise, a big construction work with its high costs and complications would be difficult to face.


Should Cell Culture Platforms Move towards EV Therapy Requirements?

Aiastui A - Front Immunol (2015)

Cell culture platform is placed in between research, hospital, and technological areas. EVs therapies derived from hospitals could transform part of the cell culture platform in a EVs sample quality service and simultaneously EV resuspension point prior to human injection.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4309209&req=5

Figure 1: Cell culture platform is placed in between research, hospital, and technological areas. EVs therapies derived from hospitals could transform part of the cell culture platform in a EVs sample quality service and simultaneously EV resuspension point prior to human injection.
Mentions: Bearing all this in mind if the cell culture platform would have to go toward EVs therapy, I would transform part of the platform in a “EVs sample quality service” (Figure 1). Otherwise, a big construction work with its high costs and complications would be difficult to face.

View Article: PubMed Central - PubMed

Affiliation: Biodonostia Health Research Institute, Cell Culture Platform , Donostia-San Sebastián , Spain.

AUTOMATICALLY GENERATED EXCERPT
Please rate it.

Progress in translational medicine crucially depends on close collaborations between three areas: technology development, research, and hospitals... This combination allows a research idea (or hypothesis) to be developed into a real concept (or product), thus producing substantial benefits to citizens... Such synergy between these areas is beginning to be found in health research institutes located in close vicinity to hospitals... Additionally, increasing developments on cell transplantation-based therapies in hospitals is leading to hand-in-hand co-working between clinicians and scientists through cell culture platforms and is evoking an internal transformation... This quality control should include at least a flow cytometry-based characterization, an ELISA-based quantification, and a nanoparticle tracking, besides purity assessment and exhaustive analysis to ensure the absence of mycoplasma, adventitious agents, and endotoxins... The establishment of EV-based therapies will lead to standardized production and manipulation protocols following good manufacturing practices (GMPs), as well as quality controls to ensure the safety and efficacy of the treatments... Hence, how will these therapies impact cell culture platforms? In addition, even if the EVs production and packing is performed in an external CDMO, resuspension of the cryopreserved EVs can be performed in the platform in our biosecurity flow hoods... This way, the EVs delivery to the hospital, ready to inject, will be achieved a minimum time, as we are already operating with other cell therapies... Bearing all this in mind if the cell culture platform would have to go toward EVs therapy, I would transform part of the platform in a “EVs sample quality service” (Figure 1)... Otherwise, a big construction work with its high costs and complications would be difficult to face... In conclusion, EVs therapies may have a great impact in the close future as new cell-based therapeutic approach; therefore, I will keep a sharp eye on EVs therapies future publications to envision the transformation of our cell culture platform toward a “EVs quality service. ” The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

No MeSH data available.